超声治疗仪联合血脂康降低血脂的临床疗效观察
|
摘要
目的:观察超声治疗仪联合血脂康在降低血脂中的应用效果。方法:选择在黑龙江省医院中西医结合科治疗的高脂血症患者80例,随机将其分为采用超声治疗仪联合血脂康治疗的观察组和仅单独采用血脂康降脂治疗的对照组,每组40例,比较两组患者的总体治疗效果和治疗前后血液中的血脂水平。结果:两组患者治疗的总有效率比较差异具有统计学意义(x2=13.536,P<0.05);观察组治疗前后组内比较血甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)和低密度脂蛋白(LDL-C),差异均具有统计学意义(t=3.265,t=4.021,t=-2.871,t=3.665;P<0.05)。对照组在治疗前后组内比较TG、TC和LDL-C差异均具有统计学意义(t=2.18,t=2.994,t=2.276;P<0.05)。治疗后两组组间比较TG、TC、HDL-C和LDL-C差异均具有统计学意义(t=-2.998,t=-3.046,t=2.887,t=3.028;P<0.05)。结论:采用超声治疗仪联合血脂康进行降脂治疗,能够显著降低患者的血脂水平,并且疗效显著,值得临床推广应用。
Objective: To observe the clinical efficacy in lowering blood lipids with ultrasound therapy device and Xuezhikang. Methods: Selected 80 cases as an object of study in Heilongjiang Provincial Hospital Integrative Medicine treated from January 2013 to July 2014, the observation group 40 cases, used ultrasound therapy device and Xuezhikang, control group 40 cases, only single use of Xuezhikang overall treatment, compared the two groups of patients before and after treatment and lipid levels in the blood. Results: The total efficiency of compared two groups of patients, a statistically significant(x2=13.536, P<0.05); compare TG group before and after treatment in the observation group, TC, HDL-C, LDL-C, were statistically significant(t=3.265, t=4.021, t=-2.871, t=3.665; P<0.05). In the control group before and after treatment group TG, TC, LDL-C were statistically significant(t=2.18, t=2.994, t=2.276; P<0.05). After treatment, the comparison between the two groups TG, TC, HDL-C, LDL-C, were statistically significant(t=-2.998, t=-3.046, t=2.887, t=3.028; P<0.05). Conclusion: Combined use of ultrasound therapy device and Xuezhikang lipid-lowering therapy, can significantly lower blood lipid levels in patients, and the effect is significant, worthy of clinical application.
Objective: To observe the clinical efficacy in lowering blood lipids with ultrasound therapy device and Xuezhikang. Methods: Selected 80 cases as an object of study in Heilongjiang Provincial Hospital Integrative Medicine treated from January 2013 to July 2014, the observation group 40 cases, used ultrasound therapy device and Xuezhikang, control group 40 cases, only single use of Xuezhikang overall treatment, compared the two groups of patients before and after treatment and lipid levels in the blood. Results: The total efficiency of compared two groups of patients, a statistically significant(x2=13.536, P<0.05); compare TG group before and after treatment in the observation group, TC, HDL-C, LDL-C, were statistically significant(t=3.265, t=4.021, t=-2.871, t=3.665; P<0.05). In the control group before and after treatment group TG, TC, LDL-C were statistically significant(t=2.18, t=2.994, t=2.276; P<0.05). After treatment, the comparison between the two groups TG, TC, HDL-C, LDL-C, were statistically significant(t=-2.998, t=-3.046, t=2.887, t=3.028; P<0.05). Conclusion: Combined use of ultrasound therapy device and Xuezhikang lipid-lowering therapy, can significantly lower blood lipid levels in patients, and the effect is significant, worthy of clinical application.
引文
[1]祁学成,曾瑞兰,唐建平.血脂康、泰嘉、拜阿司匹林联合应用对颈动脉粥样硬化斑块形成及心脑血管事件的干预[J].中国老年学杂志,2011,31(13):2428-2430.
[2]刘红军,王丽华,魏文红.血脂康对不稳定型心绞痛患者炎症因子、内皮功能及颈动脉粥样斑块的影响[J].中国实验方剂学杂志,2013,19(16):322-327.
[3]魏娜,常万松,薛迪中,等.血脂康对早期糖尿病肾病患者氧化应激的影响[J].中国全科医学,2012,15(18):2085-2087.
[4]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.
[5]李晓林,张颖,李南南.护理干预对超声治疗仪联合血脂康治疗高脂血症疗效的影响[J].中国伤残医学,2013,21(8):382-383.
[6]雷晓凤,吴岚慧.聚焦超声与微波治疗宫颈糜烂的疗效比较[J].中国社区医师:医学专业,2010,12(22):115.
[7]顾秀莲,樊济海,巢胜吾,等.血脂康对高血压合并冠心病患者135例脉压的改善作用[J].中国老年学杂志,2010,30(7):996-998.
[8]周和,林琍.血脂康联合阿托伐他汀治疗高血压合并冠心病的临床疗效[J].中国生化药物杂志,2012,33(6):873-875.
[9]张少飞.超声治疗仪对冠心病心绞痛辅助治疗研究[J].亚太传统医药,2013,9(3):191-192.
[10]Alber HF,Frick M,Sussenbacher A,et a1.Effect of atovastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease[J].Wien Med Wochenschr,2013,15(7):73-78.
[11]邹玮,王莎.超声治疗在脑卒中患者功能恢复中的作用[J].华北国防医药,2010,22(6):551-553.
[12]沈丽新,侯君,吴强鹏.非酒精脂肪肝病患者Apo B/Apo A1.比值与胰岛素抵抗的相关性研究[J].昆明医科大学学报,2013,34(9):69-72.
[13]张震洪,吴平生.血脂康对老年代谢综合征的影响[J].中国老年学杂志,2014,34(13):3597-3599.
[14]张江丽,韩清华.高血压合并冠心病患者血压特点及与心血管事件的相关性研究[J].中西医结合心脑血管病杂志,2009,7(2):141-143.
[15]唐庆,李茜,赵伊婷,等.冠状动脉病变与血浆氧化低密度脂蛋白的相关性研究[J].中国实验方剂学杂志,2012,18(12):282.
[16]赵静,王晓春,徐家立,等.辛伐他汀对冠心病合并短暂性脑缺血发作颈动脉粥样硬化软斑块的疗效观察[J].苏州大学学报:医学版,2011,31(6):987.
[2]刘红军,王丽华,魏文红.血脂康对不稳定型心绞痛患者炎症因子、内皮功能及颈动脉粥样斑块的影响[J].中国实验方剂学杂志,2013,19(16):322-327.
[3]魏娜,常万松,薛迪中,等.血脂康对早期糖尿病肾病患者氧化应激的影响[J].中国全科医学,2012,15(18):2085-2087.
[4]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.
[5]李晓林,张颖,李南南.护理干预对超声治疗仪联合血脂康治疗高脂血症疗效的影响[J].中国伤残医学,2013,21(8):382-383.
[6]雷晓凤,吴岚慧.聚焦超声与微波治疗宫颈糜烂的疗效比较[J].中国社区医师:医学专业,2010,12(22):115.
[7]顾秀莲,樊济海,巢胜吾,等.血脂康对高血压合并冠心病患者135例脉压的改善作用[J].中国老年学杂志,2010,30(7):996-998.
[8]周和,林琍.血脂康联合阿托伐他汀治疗高血压合并冠心病的临床疗效[J].中国生化药物杂志,2012,33(6):873-875.
[9]张少飞.超声治疗仪对冠心病心绞痛辅助治疗研究[J].亚太传统医药,2013,9(3):191-192.
[10]Alber HF,Frick M,Sussenbacher A,et a1.Effect of atovastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease[J].Wien Med Wochenschr,2013,15(7):73-78.
[11]邹玮,王莎.超声治疗在脑卒中患者功能恢复中的作用[J].华北国防医药,2010,22(6):551-553.
[12]沈丽新,侯君,吴强鹏.非酒精脂肪肝病患者Apo B/Apo A1.比值与胰岛素抵抗的相关性研究[J].昆明医科大学学报,2013,34(9):69-72.
[13]张震洪,吴平生.血脂康对老年代谢综合征的影响[J].中国老年学杂志,2014,34(13):3597-3599.
[14]张江丽,韩清华.高血压合并冠心病患者血压特点及与心血管事件的相关性研究[J].中西医结合心脑血管病杂志,2009,7(2):141-143.
[15]唐庆,李茜,赵伊婷,等.冠状动脉病变与血浆氧化低密度脂蛋白的相关性研究[J].中国实验方剂学杂志,2012,18(12):282.
[16]赵静,王晓春,徐家立,等.辛伐他汀对冠心病合并短暂性脑缺血发作颈动脉粥样硬化软斑块的疗效观察[J].苏州大学学报:医学版,2011,31(6):987.